Condition: Relapsed Classic Hodgkin Lymphoma · Refractory Classic Hodgkin Lymphoma · Sponsor: Navy General Hospital, Beijing
The goal of this phase 2 trial is to test the safety and efficacy of azacitidine when given together with PD-1 therapy in treating patients with relapsed/refractory classic Hodgkin lymphoma.
This description comes directly from the study's public registry record.
Liren Qian, PhD · +861066947192 · qlr2007@126.com
Always discuss trial participation with your own doctor first.
| Navy General Hospital | Beijing, Beijing Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06190067